Locust Walk launches Banyan BioInnovations – a development driven investment firm focused on launching new clinical stage companies to deliver impactful medicines faster.
A Global Life Science Investment Bank
with a Co-founder Mentality
Who We Are
Locust Walk is a global investment bank that partners with founders, executives, and board members to drive strategic transactions and create newcos to finance innovation.
Our 17-year history of success was forged through our Co-founder MentalityTM focused on innovators, our local teams embedded in Boston, San Francisco, Tokyo, Shanghai, and Beijing, and our deep understanding of how science and data translate into actionable transactions and business strategy. Our platform powers Banyan BioInnovations, an investment firm that builds new companies around best- or first-in-class clinical-stage drug assets, combining global sourcing with centralized clinical development expertise to accelerate therapies to patients.
2008
44
5
Offices In 3 Countries
80+
Core Values
Commitment to Our Client’s Success
Open & Courageous Communication
Growth Mindset
Entrepreneurial Spirit
Enjoy the Ride
Featured Recent Transactions
Exclusive financial advisor to Prazer Therapeutics in R&D Collaboration with Johnson & Johnson
Exclusive financial advisor to DURECT Corporation in sale to Bausch Health: $63M Upfront + Up to $350M in CVRs
Exclusive financial advisor to Checkpoint Therapeutics in sale to Sun Pharma for up to $416M
Latest News and Events
Banyan BioInnovations
Read more: Banyan BioInnovations announces its launch as an investment firm that identifies best or first in class clinical stage assets, forms NewCos around them, and provides experienced centralized support to accelerate drug
Sun pharma to acquire checkpoint Therapeutics
Read more: for a full summary of the event. Locust Walk co-hosted the third annual Align Summit in Boston, an event organized by MassBio and co-hosted by McKinsey to spotlight emerging biotech innovation and foster meaningful connections across the ecosystem.
Bausch Health to Acquire DURECT Corporation
Read more: Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ: DRRX) today announced a definitive agreement under which Bausch Health will indirectly acquire DURECT Corporation, including a novel therapeutic molecule, larsucosterol, which can harness the power of epigenetic modulation.
Read more: As more drugs stall between early data and approval, Geoffrey Meyerson’s Banyan BioInnovations is testing a new investment approach for biotech’s most expensive and underfunded phase.
Build with Us
